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2002). Hence Akt becomes activated and in turn phos-
phorylates a number of downstream critical targets that
regulate cell death such as Bad and caspase-9 or protein
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synthesis such as the mammalian target of rapamycinShilai Bao,1 Norihisa Hanada,1 Hitomi Saso,1
(mTOR) in translation initiation or other metabolic func-Ryuji Kobayashi,2 and Mien-Chie Hung1,3,*
tions (Nicholson and Anderson, 2002).1Department of Molecular and Cellular Oncology
In addition to translational modification, Akt regulates2 Department of Molecular Pathology
transcription through modulation of the activity of Fork-M.D. Anderson Cancer Center
head FOXO transcription factors FOXO1 (FKHR),3 Graduate School of Biomedical Sciences
FOXO3a (FKHRL1), and FOXO4 (AFX) by phosphorylat-The University of Texas
ing them at three conserved serine/threonine residuesHouston, Texas 77030
(Thr32, Ser253, and Ser315 of FOXO3a) (reviewed in
Burgering and Kops, 2002; Tran et al., 2003). This leads
to the release of FOXO transcription factors from theSummary
DNA and translocation to the cytoplasm, where 14-3-3
protein binds to the phosphorylated FOXO factors andNuclear exclusion of the forkhead transcription factor
retains them in the cytoplasm presumably by maskingFOXO3a by protein kinase Akt contributes to cell sur-
their nuclear localization signal and preventing their re-vival. We investigated the pathological relationship be-
entry into the nucleus. However, in the absence oftween phosphoylated-Akt (Akt-p) and FOXO3a in pri-
growth or survival signal stimulation, Akt is inactivatedmary tumors. Surprisingly, FOXO3a was found to be
in the quiescent cells; this inactivation results in reten-excluded from the nuclei of some tumors lacking
tion of FOXO factors in the nucleus and thereby upregu-Akt-p, suggesting an Akt-independent mechanism of
lates expression of specific target genes that modulateregulating FOXO3a localization. We provide evidence
the metabolic state (Carlsson and Mahlapuu, 2002), con-for such a mechanism by showing that IB kinase (IKK)
trol cell cycle progression (e.g, cyclin-dependent kinasephysically interacts with, phosphorylates, and inhibits
inhibitor p27kip1 [Medema et al., 2000] and Rb2 [P130]FOXO3a independent of Akt and causes proteolysis of
[Kops et al., 2002]), regulate the mitotic program (e.g.,FOXO3a via the Ub-dependent proteasome pathway.
cyclin B and Polo-like kinase [Alvarez et al., 2001]), orCytoplasmic FOXO3a correlates with expression of
induce cellular apoptosis (e.g., Fas ligand [Brunet et al.,IKK or Akt-p in many tumors and associates with
1999] and Bim [Burgering and Kops, 2002]). Therefore,poor survival in breast cancer. Further, constitutive
FOXO transcription factors play a pivotal role in regulat-expression of IKK promotes cell proliferation and
ing cell proliferation and survival.tumorigenesis that can be overridden by FOXO3a. These
Recent studies in C. elegans (DAF-16), Drosophilaresults suggest the negative regulation of FOXO fac-
(dFOXO), and mammals reveal that the Akt/FOXO signal-tors by IKK as a key mechanism for promoting cell
ing pathway is largely conserved in metazoans. In inver-growth and tumorigenesis.
tebrates, this pathway plays a critical role in regulating
body size and life span (Burgering and Kops, 2002; Puig
Introduction et al., 2003). In mammalian cells, activation of FOXO
transcription factors can induce either cell cycle arrest
Constitutive activation of cell survival signaling is a gen- or apoptosis probably depending on the physiological
eral mechanism underlying tumor development and re- conditions and cell types (Burgering and Kops, 2002;
sistance to therapy and constitutes a major clinical prob- Tran et al., 2003); and therefore, it has been postulated
lem in cancer (Hanahan and Weinberg, 2000). One of that FOXO factors may inhibit cell transformation or
the key survival signaling mechanisms is the PtdIns- tumorigenesis. For instance, it has been shown that
3-kinase (PI3K)/Akt pathway that can be activated by FOXO3a and FOXO1 are sequestered in the cytoplasm
oncogenes, and the catalytic subunit of PI3K and Akt and become inactivated in certain tumor cell lines defi-
have been aberrantly expressed or constitutively acti- cient in PTEN, a tumor suppressor that blocks the PI3K/
vated in several tumor malignancies (reviewed in Vi- Akt signaling pathway (Medema et al., 2000; Nakamura
vanco and Sawyers, 2002; Nicholson and Anderson, et al., 2000; Vazquez and Sellers, 2000). While re-expres-
2002). Upon stimulation with growth factors, their recep- sion of PTEN in the PTEN-negative tumor cells induces
tors trigger PI3K to increase production of PtdIns-3,4,5- cellular apoptosis or upregulates p27kip1 that results in
triphosphate that binds to the pleckstrin homology do- cell cycle arrest in G1 phase, the same phenotypes can
main of Akt, resulting in recruitment of Akt to the plasma also be exerted by overexpression of FOXO factors in
membrane. A conformational change of Akt follows that these cells (Nakamura et al., 2000), suggesting that acti-
enables residues Thr308 and Ser473 of Akt to be phos- vation of FOXO factors may play a role in PTEN-medi-
phorylated by upstream kinases (Vivanco and Sawyers, ated tumor suppression. Thus, nuclear exclusion of
FOXO factors regulated by the PI3K/Akt pathway not
only plays a critical role in survival and antiapoptosis of*Correspondence: michu@mdanderson.org (M.C.-T.H.), mhung@
normal cells but contributes to the pathogenesis andmdanderson.org (M.-C.H.)
4These authors contributed equally to this work. development of cancer (Nicholson and Anderson, 2002).
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However, the pathological correlation between nuclear mainly localized in the cytoplasm of tumor tissues with
a high level of Akt-p (Figure 1A, case 1) while FOXO3aexclusion of FOXO factors and phosphoylated-Akt
(Akt-p, activated Akt) in primary tumors has not been was largely located in the nucleus of many tumors with
negative Akt-p (Case 2). However, in a significant num-reported and little is known about the role and signifi-
cance of FOXO factors in tumorigenesis. ber (23 cases) of tumor specimens lacking detectable
Akt-p, FOXO3a was still predominantly confined in theIn an attempt to investigate the correlation between
expression of FOXO3a and Akt-p in human primary cytoplasm (case 3), suggesting that other mechanisms
may contribute to nuclear exclusion of FOXO3a in thesebreast tumors, we unexpectedly found that in some tu-
mor specimens with negative Akt-p, FOXO3a was still tumors. To examine a potential involvement of IKK (a
major catalytic subunit of IKK) in breast tumors, weexcluded from the nucleus, suggesting that other mech-
anisms may retain FOXO3a in the cytoplasm of tumor found that FOXO3a was excluded from the nucleus
when the tumors expressed IKK but without detectabletissues. For instance, the IB kinase (IKK) signaling path-
way has been established as a key survival and antiapo- Akt-p (case 3), while FOXO3a was located in the nucleus
of tumors with negative IKK and Akt-p (case 2). Amongptotic mechanism, and aberrant expression of IKK has
been implicated in constitutive activation of NF-B in 131 tumor specimens examined, 113 tumors were FOXO3a
positive and cytoplasmic localization of FOXO3a washuman breast cancer cell lines and primary tumors (re-
viewed in Karin et al., 2002). Thus, it seems to be plausi- detected in the majority (90%) of these 113 tumors with
positive IKK and Akt-p (Figure 1B). However, FOXO3able that the IKK/NF-B pathway may be involved in regu-
lation of FOXO factors and leading to cell survival. The was found in the cytoplasm only in a small fraction (30%)
of these 113 tumor specimens with negative IKK andprimary form of NF-B is a heterodimer of p50 and p65
(RelA) and is retained as a latent form in the cytoplasm Akt-p, suggesting that cytoplasmic FOXO3a correlates
with the expression of IKK and Akt-p. Moreover, weof resting cells by IB, an inhibitor of NF-B. NF-B is
activated by stimulation of an IKK complex, containing validated the positive staining of IKK and Akt-p by
using two different Ab against IKK, and Ab specific toIKK//, which phosphorylates IB and triggers its ubi-
quitination (Ub)-dependent degradation through the Akt-p (Thr308) and Akt-p (Ser473) on randomly selected
primary breast tumor specimens. Both Thr308 andproteasome pathway (Karin et al., 2002; Karin and Ben-
Neriah, 2000). This leads to nuclear translocation of acti- Ser473 are known to be phosphoylated in activated Akt.
The strong correlative staining between Akt-p (Thr308)vated NF-B and upregulation of its target genes. It has
been suggested that inhibition of NF-B activation plays and Akt-p (Ser473) (Figure 1C) further strengthens the
significance of Figures 1A and 1B.an important role in the tumor necrosis factor (TNF)-
induced apoptosis. The activity of IKK is often activated To further test whether this correlation is a general
phenomenon in multiple tumors and normal tissues, weconstitutively, which results in the sustained activation
of members of the NF-B family during the development examined a number of human primary tumor specimens
and normal tissues by IHC. Our results showed thatof breast carcinoma (reviewed by Karin et al., 2002).
This elevated NF-B activity may lead to aberrant upreg- the same functional relationship between cytoplasmic
FOXO3a and positive IKK and Akt-p occurred not onlyulation of certain tumorigenic or angiogenic factors, che-
mokines, adhesion proteins, and inhibitors of apoptosis. in other tumor entities, but also in normal tissues (Fig-
ures 1D and 1E), suggesting that the correlation betweenStrikingly, we have recently found that the level of nu-
clear FOXO3a inversely correlates with expression of cytoplasmic FOXO3a localization and positive IKK and
Akt-p may be a general phenomenon. We compared theIKK in the human breast tumor specimens and posi-
tively correlates with the survival rate in breast cancer. expression of Akt-p, IKK, and FOXO3a in tumor tissues
with the patient survival follow-up and found that cyto-We have further demonstrated that IKK inhibits FOXO3a
activity, physically interacts with and phosphorylates plasmic distribution (N  C) of FOXO3a was strikingly
linked to a poor survival in patients with breast cancerFOXO3a independent of Akt, and causes proteolysis of
FOXO3a via the Ub-dependent proteasome pathway. (Figure 2A). However, negative IKK, Akt-p, and a
greater nuclear localization (N  C) of FOXO3a wereDownregulation of FOXO3a by IKK can induce cell prolif-
eration and tumorigenesis in breast cancer cells. Our significantly associated with an increase of overall sur-
vival (Figures 2B–2D). These results suggest that cyto-results suggest that negative regulation of FOXO factors
by IKK is a key mechanism for promoting tumor cell plasmic localization of FOXO3a and expression of IKK
and Akt-p negatively correlate with the survival rate ingrowth and tumorigenesis.
breast cancer.
Results
IKK Represses FOXO3a Transactivation Activity
and Nuclear Translocation Independent of AktNuclear Exclusion of FOXO3a Correlates
with Expression of IKK and Akt-p in Tumors The correlation between cytoplasmic FOXO3a and IKK
in both normal and tumor tissues promoted us to exam-and Normal Tissues and Is Associated
with Poor Survival in Breast Cancer ine the regulatory role of IKK on FOXO3a activity. We
tested the effect of IKK on the FOXO3a-dependentTo determine the physiological or pathological relation-
ship between expression of FOXO3a and Akt-p in vivo, transcriptional activation of a promoter containing the
FOXO-responsive elements (FRE) that drive a luciferasewe examined the level of FOXO3a and Akt-p proteins
in 131 human primary breast tumor specimens by immu- (luc) reporter gene. Cotransfection of FOXO3a together
with IKK or IKK into 293T cells resulted in strongnohistochemical (IHC) staining and the survival data of
the corresponding patients. As expected, FOXO3a was inhibition of FOXO3a activity, whereas cotransfection of
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Figure 1. Nuclear Exclusion of FOXO3a Cor-
relates with Expression of IKK and Akt-p in
Many Types of Tumors and Normal Tissues
(A) Primary human breast tumor specimens
were stained with antibodies (Ab) specific to
Akt-p (Thr308) or Akt-p (Ser473), FOXO3a,
and IKK.
(B) An average (%) of FOXO3a localization in
the nucleus or cytoplasm was determined.
(C) A correlation analysis between Akt-p
(Thr308) and Akt-p (Ser473) IHC staining sig-
nals was performed by Spearman rank corre-
lation.
(D) Human primary tumor specimens were
stained with Ab specific to Akt-p (Thr308),
FOXO3a, and IKK. AC and SCC denote ade-
nocarcinoma and squamous cell carcinoma,
respectively. An asterisk marks a macro-
phage.
(E) Human normal tissues were stained with
Ab as indicated.
FOXO3a with either IKK or a dominant-negative IKK fection with a luc reporter under the control of p27Kip1
promoter, which is a transcriptional target of FOXO3a.(nIKK) did not affect FOXO3a activity (Figure 3A). To
rule out the possibility that the repression of FOXO3a Consistent with the FRE-luc results, FOXO3a activity
was significantly reduced by IKK on the p27Kip1 pro-activity was through an Akt-dependent pathway, we
tested a mutant FOXO3a with all three Akt recognition moter (Figure 3D). A similar inhibitory pattern of FOXO3a
by IKK was observed on the cotransfection experimentssites mutated (FOXO3a-A3) in the cotransfection experi-
ments and showed that FOXO3a-A3 activity was still with a luc reporter driven by the promoter of Fas-ligand
(FasL) (Figure 3E), supporting that IKK can inhibit thesuppressed by IKK in the same fashion as the wild-
type (wt) FOXO3a (Figure 3A), suggesting that the IKK- native FOXO3a-targeted promoters.
To understand the molecular mechanism for the IKK-mediated inhibition of FOXO3a function is not Akt de-
pendent. To further support this notion, we compared mediated inhibition of FOXO3a activity, we investigated
whether the subcellular distribution of FOXO3a is regu-FOXO3a activity in between human breast cancer MDA-
MB-453 (453) and 453-nAkt (expressing a dominant- lated by IKK. We cotransfected the FOXO3a-GFP vector
with the various IKK constructs into 293T cells and ex-negative Akt) cell lines and showed similar inhibitory
effects on FOXO3a by IKK in 453 and 453-nAkt cells amined the subcellular localization of FOXO3a-GFP.
While FOXO3a-GFP protein was localized primarily(Figure 3B), supporting that the IKK-mediated inhibition
of FOXO3a is Akt independent and may be a general within the nuclei of cells cotransfected with a control
vector or IKK, FOXO3a-GFP was largely excluded fromphenomenon in multiple cell types. We further showed
that this IKK-mediated inhibition of FOXO3a was depen- the nucleus and detected in the cytoplasm when it was
cotransfected with IKK or IKK (Figure 3F). This IKK-dent on the dose of IKK/ but not nIKK/ (Figure
3C). To determine whether IKK could regulate FOXO3a and IKK-dependent nuclear exclusion of FOXO3a-GFP
was further verified by an average of500 GFP-positiveactivity on the native promoters, we examined the ef-
fects of various IKK constructs on FOXO3a by cotrans- cells, and a parallel comparison with the effect of Akt
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Figure 2. Cytoplasmic FOXO3a and Expres-
sion of IKK and Akt-p Are Associated with
Poor Survival in Breast Cancer
(A) The Kaplan-Meier overall survival curve
shows that the predominant cytoplasmic
FOXO3a group (N  C, blue) was linked with
a strong reduction of overall survival time as
compared to that of the nuclear FOXO3a (N
C, red) group.
(B) The survival curves show that the Akt-p
and IKK positive group (blue) was associ-
ated with a decreased survival.
(C) The survival curves indicated that the de-
tection of positive IKK and predominant cy-
toplasmic FOXO3a (blue) was linked with a
strong reduction of overall survival.
(D) A similar survival correlation was obtained
as in (C) when comparing the three parame-
ters of Akt-p and IKK and FOXO3a.
by cotransfection with a constitutively active Akt (Akt- proteins and showed that IKK interacted with the car-
boxyl-portion of FOXO3a specifically but not the N-ter-DD) (Figure 3G).
minal domain of FOXO3a (Figure 4D).
Given this physical association, we examined whether
IKK Interacts with and Phosphorylates IKK could phosphorylate FOXO3a in vivo. We cotrans-
FOXO3a In Vivo and In Vitro fected HA-FOXO3a with the indicated IKK vectors into
To elucidate the mechanism by which IKK can regulate cells, followed by orthophosphate (32Pi) labeling, and
the cellular localization and activity of FOXO3a, we ex- performed IP with an anti-HA. Indeed, HA-FOXO3a was
amined if endogenous FOXO3a is physically associated phosphorylated in vivo and phosphorylation of HA-
with IKK by reciprocal coimmunoprecipitation (IP) fol- FOXO3a was significantly enhanced by IKK or IKK
lowed by an immunoblotting (IB) analysis with lysates (to a lesser degree) but not by nIKK, supporting that
of 453 and SKOV3-ip1 (ip1) cells using antibodies (Ab) FOXO3a is a target for IKK (Figure 4E). To address if
against FOXO3a and IKK. Our results showed that en- IKK could phosphorylate FOXO3a in vitro, we produced
dogenous FOXO3a was specifically associated with en- several overlapping fragments of FOXO3a (FO3a) fused
dogenous IKK in vivo (Figure 4A). To examine if this to GST and used these proteins as substrates in an
association is inducible upon activation of endogenous IKK-immunocomplex kinase assay and showed that
IKKby TNF treatment, we performed the co-IP experi- the C-terminal portion Gst-FO3a (301–673) but not the
ments with lysates of MCF-7 cells treated or untreated N-terminal portion Gst-FO3a (1–300) was phosphory-
with TNF plus or minus proteasome inhibitor MG132. lated by IKK and the intensity of phosphorylation was
We found that the binding between endogenous IKK comparable to that of Gst-IB, a known substrate of
and FOXO3a appeared to be enhanced by MG132 treat- IKK (Figure 4F). Further analysis indicated that most
ment, and this association was slightly increased by phosphorylation was detected on the fragment FO3a
TNF treatment (Figure 4B). (626–673) and the rest of fragments were not phosphory-
To further confirm this association with the tag-spe- lated significantly (Figure 4G), suggesting that the pri-
cific Ab, we cotransfected FOXO3a-Myc with Flag-IKK mary phosphorylation site(s) may locate within the re-
or -IKK into cells and examined their interactions by gion of residues 626–673. To narrow down the potential
reciprocal IP/IB using anti-Myc and -Flag and showed phosphorylation sites, we synthesized peptides corre-
that the exogenously expressed FOXO3a-Myc specifi- sponding to the candidate serine residues among frag-
cally interacted with Flag-IKK and -IKK in vivo (Figure ments FO3a (301–346), FO3a (579–625), and FO3a (626–
4C). To verify a direct binding between FOXO3a and 673) and a peptide consisting of several serine residues
IKK in vitro, we performed the glutathione S-transferase within the region of FO3a (393–439) (Figure 4G) as a
control and used them as substrates in the IKK-kinase(GST) pulldown assays with the GST-FOXO3a fusion
IKK Represses FOXO3a
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Figure 3. IKK Inhibits FOXO3a Transactivation Activity and Its Nuclear Translocation
(A) Lysates of 293T cotransfected with FRE-luc, pRL-TK, and FOXO3a plus the marked IKK constructs were subjected to luciferase (luc)
assays. The relative luc activity was normalized.
(B) Lysates of 453 or 453-nAkt cotransfected with the indicated DNA vectors were subjected to luc assays.
(C) Lysates of 293T cotransfected with FRE-luc and FOXO3a plus different doses of IKK/ or nIKK/ were subjected to luc assays.
(D) Lysates of 293T cotransfected with p27Kip1-luc and FOXO3a plus the indicated IKK constructs were subjected to luc assays.
(E) Lysates of 293T cotransfected with FasL-luc and FOXO3a plus the various IKK constructs were subjected to luc assays.
(F) 293T cotransfected with FOXO3a-GFP plus Flag-IKK or Flag-IKK or HA-IKK were subjected to GFP or anti-Flag immunofluorescence.
(G) An average of GFP-positive cells in the nucleus or cytoplasm was determined.
assays. The results indicated that the major phosphory- alanine (S644A) and found that phosphorylation of the
mutant protein was abrogated (Figure 4I), suggestinglation occurred on the peptide 625–648 (Figure 4H),
which is consistent with the primary phosphorylation that Ser644 is the predominant site of IKKphosphoryla-
tion on FOXO3a. However, we could not rule out certaindetected in the fragment FO3a (626–673) (Figure 4G).
Since Ser644 in the segment of FO3a (626–673) is con- minor target sites matching the putative IKK recognition
sequences for phosphorylation in FOXO3a (Figure 4J)served with the putative IKK phosphorylation sequences
(Karin and Ben-Neriah, 2000), we mutated Ser644 into that might be phosphorylated by IKK.
Cell
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Figure 4. IKK Interacts with and Phosphorylates FOXO3a In Vivo and In Vitro
(A) Lysates of 453 and ip1 were subjected to reciprocal IP/IB (anti-FOXO3a/anti-IKK).
(B) Lysates of MCF-7 treated or untreated with TNF plus or minus MG132 were subjected to IP/IB (anti-IKK/anti-FOXO3a).
(C) Lysates of 293T cotransfected with FOXO3a-Myc plus Flag-IKK or -IKK were analyzed by IP/IB.
(D) Lysates of 293T transfected with Flag-IKK or -IKK were incubated with GST-FOXO3a (FO3a) proteins, followed by IB.
(E) Lysates of 293T cotransfected with FOXO3a plus the indicated IKK and labeled with [32P]orthophosphate were subjected to IP (anti-HA)
and autoradiograph.
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To confirm that S644 is the site of IKK-catalyzed phos- constructs or a control vector. Strikingly, we observed
not only a significant decrease of HA-FOXO3a in thephorylation of the endogenous FOXO3a protein in re-
sponse to TNF, we raised an Ab against a phosphopep- cells cotransfected with HA-FOXO3a and IKK, but an
evident high M.W. band (150 kDa) that could be de-tide corresponding to the phosphorylation site of S644
and used this Ab for IB analysis. We first demonstrated tected with either an anti-HA or anti-FOXO3a (Figure
5A). A similar high M.W. band (to a lesser degree) wasthat this Ab recognized FOXO3a-GFP in 293T cells co-
transfected with FOXO3a-GFP and IKK but did not also detected in cells cotransfected with HA-FOXO3a
and IKK but not in the samples with mutant nIKK orrecognize FOXO3a-GFP in cells cotransfected with
. Since Ub is a well-known protein modification thatFOXO3a-GFP and nIKK (Figure 4K). Neither could this
induces protein degradation through the proteasomeAb recognize FOXO3a-(S644A)-GFP in which S644 had
pathway, we examined if the IKK-induced protein modi-been converted to alanine (S644A) (Figure 4K), indicating
fication of FOXO3a was through Ub. To this end, wethat this Ab recognizes FOXO3a specifically when it is
cotransfected cells with FOXO3a-Myc together with HA-phosphorylated at S644 (FOXO3a-P-S644). Moreover,
Ub plus the various IKK vectors and examined the HA-this Ab recognized FOXO3a-GFP with TNF treatment
tagged protein patterns of FOXO3a. After IP with anmore significantly than that without treatment (Figure
anti-Myc, a characteristic pattern of polyUb on Myc-4L), suggesting that this Ab can recognize the TNF-
FOXO3a was readily detected by IB with an anti-HA oninduced phosphorylation of FOXO3a. We next examined
the samples cotransfected with IKK or IKK (to a lesserwhether this Ab could detect endogenous FOXO3a-
degree) but not with IKK or nIKK// (Figure 5B), sug-P-S644 in response to TNF. We found that treatment
gesting that Ub of FOXO3a is dependent on the IKKof MCF-7 cells with TNF stimulated phosphorylation
kinase activity. In addition, we tested if sumoylation wasof a 100 kDa protein that could also be recognized by
involved in the IKK-mediated modification of FOXO3a byother anti-FOXO3a Ab, whereas phosphorylation at
cotransfecting cells with Myc-FOXO3a and HA-SUMO1S644 of FOXO3a was not detectable in MCF-7 without
vector with or without IKK. The results showed that noTNF treatment (Figure 4M). We further tested if this
HA-tagged high M.W. band of FOXO3a was detectedphospho-Ab could assess nuclear exclusion of endoge-
by IB with an anti-HA after IP with an anti-Myc, sug-nous FOXO3a-P-S644 in response to TNF by immuno-
gesting that the IKK-mediated FOXO3a modificationfluorescence. Indeed, we found that endogenous
may be independent of sumoylation (Figure 5B). As aFOXO3a recognized by this Ab was predominantly ex-
control, we detected a band at 12 kDa of SUMO1 bycluded from the nucleus and detected in the cytoplasm
IB (not shown). Furthermore, this IKK-mediated Ub ofof MCF-7 treated with TNF, while FOXO3a was not
FOXO3a was supported by the facts that the IKK-depen-detected with this Ab without TNF treatment. These
dent decrease of FOXO3a activity could be significantlyresults are consistent with our previous data on the IKK-
recovered by MG132 treatment (Figure 5C) and the IKK-dependent nuclear exclusion of FOXO3a-GFP (Figure
induced degradation of HA-FOXO3a could be blocked3F). Moreover, the binding of this Ab to endogenous
by multiple proteasome inhibitors with different modesFOXO3a-P-S644 in response to TNF was abrogated
of action (Figure 5D). To ascertain that endogenouswith a blocking peptide, whereas the signal of immuno-
FOXO3a is also ubiquitinated in an IKK-dependent man-fluorescence with this Ab (green) was largely unaffected
ner, we examined endogenous FOXO3a in lysates pre-in the presence of a control peptide (Figure 4N), sug-
pared from wt or IKK-deficient (/) mouse embryonicgesting that the binding of this phospho-Ab to the en-
fibroblasts (MEF) treated or untreated with TNF anddogenous FOXO3a protein is specific to the phosphory-
showed that a high M.W. band of FOXO3a (Ub-FOXO3a)lated state of S644 residue. Taken together, our results
was mainly detected in the wt MEF with TNF treatment,strongly suggest that phosphorylation of the endoge-
whereas this band was not evident in IKK (/) MEFnous FOXO3a at S644 is induced by endogenous IKK
in the presence of TNF (Figure 5E), suggesting thatin response to its physiological stimulation.
TNF induces Ub of endogenous FOXO3a in an
IKK-dependent manner.
IKK Induces Ubiquitination and Degradation To substantiate whether the level of Ub of endogenous
of FOXO3a through the Proteasome Pathway FOXO3a observed in response to IKK activation is ef-
that Is Dependent on Ser644 of FOXO3a fective to functionally degrade FOXO3a in cells, we per-
To further address the mechanism for the IKK-mediated formed a timecourse of the TNF-induced effects on
FOXO3a inactivation, we investigated the level of FOXO3a total protein level plus or minus MG132 and
FOXO3a protein in whole lysates prepared from cells showed that endogenous FOXO3a was significantly re-
moved from cells in the absence of MG132 after TNFcotransfected with HA-FOXO3a plus the various IKK
(F–I) Lysates of 293T transfected with HA-IKK were IP with an anti-HA, and kinase assays were performed with the various FOXO3a Gst-
fusion proteins (F), the Gst-FO3a sequential fusion fragments (G), synthetic peptides (H), and wt or the S644A mutant Gst-FO3a (626–673)
fragment (I).
(J) The putative IKK consensus sequences for phosphorylation (S, serine; T, threonine; 	, hydrophobic amino acid; and X, any amino acid).
(K) Lysates of 293T cotransfected with the indicated vectors were analyzed by IP/IB (anti-FOXO3a/anti-FOXO3a-P-S644).
(L) Lysates of 293T transfected with FOXO3a-GFP plus or minus TNF were analyzed by IP/IB (anti-GFP/anti-FOXO3a-P-S644).
(M) Lysates of MCF-7 treated or untreated with TNF plus MG132 were subjected to IB.
(N) MCF-7 treated or untreated with TNF plus MG132 were stained with anti-FOXO3a-P-S644 with or without a blocking or control peptide
and followed by immunofluorescence.
Cell
232
Figure 5. IKK Induces Ubiquitination and Degradation of FOXO3a via the Proteasome Pathway that Is Dependent on Ser644 of FOXO3a
(A) Lysates of 293T cotransfected with HA-FOXO3a plus the indicated IKK vectors were analyzed by IB.
(B) Lysates of 293T cotransfected with HA-Ub or HA-SUMO1 plus FOXO3a-Myc and the various IKK vectors were IP/IB (anti-Myc/anti-HA).
(C) Lysates of 293T cotransfected with the marked vectors with or without MG132 were subjected to luc assays.
(D) Lysates of 293T cotransfected with HA-FOXO3a and IKK, treated with the indicated proteasome inhibitors, were analyzed by IB.
(E) Lysates of the wt or IKK (/) MEF, treated or untreated with TNF, were analyzed by IB.
(F) Lysates of MCF-7 untreated or treated with TNF for various time periods plus or minus MG132 were subjected to IB.
(G) Lysates of the wt or IKK (/) MEF cotransfected with FRE-luc and pRL-TK, with or without TNF, were subjected to luc assays.
(H) Lysates of 293T cotransfected with the indicated vectors were subjected to IP/IB (anti-Myc/anti-His).
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treatment for 60 min, while the majority of FOXO3a was expression was also reduced in 453- cells due to inhibi-
tion of FOXO3a activity (Figure 6A). Since degradationnot degraded in the presence of MG132 after TNF treat-
ment (Figure 5F). We further compared the ability of of IB leads to activation of NF-B, which is associated
with mitogenic stimulation, upregulation of cyclin D1IKK to inhibit endogenous FOXO3a activity in response
to TNF in MEF by using the luc assays with or without expression, and cell proliferation (Joyce et al., 2001),
we next tested if constitutive expression of IKK couldTNF treatment and showed that FOXO3a activity was
significantly suppressed in wt MEF but not in IKK (/) promote cell cycle progression and proliferation. After
cells were arrested with serum starvation and treatedMEF upon TNF treatment (Figure 5G), indicating that
IKK is required for the TNF-mediated repression of with a reversible cell cycle inhibitor mimosine to syn-
chronize cells in G1 phase of the cell cycle, we measuredFOXO3a activity. Taken together, these results indicate
that the degree of Ub of endogenous FOXO3a in re- the percentage of cells at S phase of the cell cycle as
the rate of cell cycle entry by flow cytometry and foundsponse to IKK activation is sufficient to functionally
remove FOXO3a from cells, and normal activation of that the 453- cells entered the cell cycle significantly
faster than 453-C and 453-n cells (Figure 6B). Consis-IKK by TNF leads to an inactivation of endogenous
FOXO3a in MEF in an IKK-dependent manner. tently, the proliferation rates of 453- cells were signifi-
cantly greater than those of 453-C cells (Figure 6C),To determine if phosphorylation of Ser644 on FOXO3a
was required by this IKK-mediated Ub of FOXO3a, we suggesting that constitutive expression of IKK stimu-
lates cell cycle progression and proliferation.cotransfected cells with IKK and His-Ub plus FOXO3a-
Myc or mutant FOXO3a-(S644A)-Myc and examined the To investigate if this stimulatory effect of IKK on cell
proliferation was via repression of FOXO3a, we trans-His-tagged protein patterns of FOXO3a. A characteristic
pattern of polyUb on FOXO3a-Myc was readily detected fected HA-FOXO3a into 453-5 cells and selected two
independent cell clones (453-5-FO5 and -FO18) withby IP/IB (anti-Myc/anti-His) on the samples cotrans-
fected with IKK and FOXO3a-Myc but not with FOXO3a- high levels of FOXO3a (FO) expression (Figure 6D). Since
FOXO3a might be antagonized by IKK in 453-5 cells,(S644A)-Myc (Figure 5H), suggesting that the IKK-indcued
Ub of FOXO3a depends on phosphorylation of Ser644. we examined whether FOXO3a expressed in 453-5-
FO5 cells was functionally localized in the nucleus andTo test if the IKK-mediated inhibition of FOXO3a function
is Ser644 dependent, we compared the FOXO3a activity recruited to the promoter of its target gene p27Kip1
using chromatin immunoprecipitation (ChIP). Indeed, theand nuclear translocation between FOXO3a-GFP and
FOXO3a-(S644A)-GFP in the cotransfection experi- p27Kip1 promoter occupancy by FOXO3a, particularly
to the region containing the putative FOXO3a bindingments and showed that the activity and nuclear localiza-
tion of FOXO3a-(S644A)-GFP was no longer negatively sites, was observed in 453-C1 and enhanced in 453-5-
FO5 but not detectable in 453-5 (Figure 6E), indicatingregulated by IKK (Figures 5I–5K) in cells even with a
high level of IKK. We further verified that the IKK- that re-expression of FOXO3a constitutively in 453-5-
FO5 can overcome the negative regulation of IKK andmediated inhibition of FOXO3a activity was dependent
on Ser644 by transfecting 453 cells with IKK plus enhance the physical association of FOXO3a with the
promoter of its target gene. The proliferation rates ofFOXO3a-GFP or FOXO3a-(S644A)-GFP and assessing
expression of p27Kip1 by immunofluorescence with an 453-5-FO5 and -FO18 were reduced or comparable
with those of 453-C1 or -C5 (Figure 6C), implying thatanti-p27Kip1. The p27Kip1 expression was enhanced in
the FOXO3a-(S644A)-GFP-transfected cells as com- cell proliferation stimulated by IKK can be overridden
by constitutive expression of FOXO3a. In addition, thepared to that in the FOXO3a-GFP-transfected cells (Fig-
ure 5L), confirming that Ser644 is required for the proliferation rates of 453-C1-FOpool were also signifi-
cantly decreased (Figure 6C), suggesting that expres-IKK-mediated repression of FOXO3a.
sion of FOXO3a may exert a general inhibitory effect on
cell growth. Taken together, our results suggest that aIKK Stimulates Cell Cycle Progression, Proliferation,
and Tumorigenesis that Can Be Overridden mechanism by which IKK stimulates cell cycle progres-
sion and proliferation is through suppression of FOXO3aby Expression of FOXO3a
To determine whether constitutive expression of IKK activity.
Since IKK can stimulate cell proliferation and its ex-could decrease FOXO3a expression in cell lines stably
expressing IKK, we generated several 453-IKK and pression contributes to a prediction of poor survival for
the breast cancer patients (Figures 2B–2D), we tested453-nIKK stable transfectants (designated as 453-
and 453-n, respectively). We first examined the expres- if constitutive expression of IKK in breast cancer cells
can enhance tumorigenesis in vivo. The 453-, -n, andsions of endogenous FOXO3a, IB, and p27Kip1 in the
various 453-C (the vector-transfected control cell lines), -C cells were injected into the mammary fat pads of
nude mice. In agreement with wt 453, injection of 453-453-, 453-n, and 453-nAkt cell lines by IB analysis.
The levels of FOXO3a and IB proteins were signifi- C1, -C2, -n2, and -n4 did not initiate or maintain tu-
morigenesis in mice (Figure 6F). However, inoculation ofcantly decreased in 453- cell lines, and the p27Kip1
(I) Lysates of 453 cotransfected with the marked vectors were subjected to luc assays.
(J) MCF-7 were cotransfected with the vectors as marked and subjected to immunofluorescence.
(K) An average of 200 GFP-positive cells in the nucleus or cytoplasm was determined.
(L) 453 cotransfected with the indicated vectors were subjected to immunofluorescence. An average of p27Kip1-positive nuclei in the total
GFP-positive cells was determined.
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Figure 6. IKK Stimulates Cell Cycle Progression, Proliferation, and Tumorigenesis that Can Be Overridden by Re-expression of FOXO3a
(A) Lysates of 453 lines as marked were analyzed by IB.
(B) The various 453 lines were arrested, synchronized, and followed by cell cycle analysis.
(C) Cells were synchronized and their proliferation rates were determined (pool, pooled clones; FO, cell line stably transfected with FOXO3a).
(D) Lysates of the indicated 453 lines were analyzed by IB.
(E) Association of FOXO3a with the endogenous p27Kip1 promoter in vivo was shown by the ChIP assays with the marked 453 lines.
(F) The various 453 lines were injected into the mammary fat pads of nude mice.
(G) Similar mouse models were performed with 453-5, 453-5-FO5, and -FO18.
(H) 453-5 cells were pretreated with MG132 DMSO before injection into nude mice, and MG132 or DMSO was injected into the tumor-bearing
mice twice/week.
the 453-5 and -51 into nude mice induced mammary indicating that tumorigenesis induced by IKK can be
suppressed by re-expression of FOXO3a. Since thetumors consistently (Figure 6F), suggesting that consti-
tutive expression of IKK can promote tumorigenesis IKK-mediated repression of FOXO3a could be recov-
ered by MG132 treatment (Figures 5C and 5D), as anin vivo. To determine if this promoting effect of IKK on
tumorigenesis is via inhibition of FOXO3a, we performed alternative approach to confirm the inhibitory role of
FOXO3a in tumorigenesis, we further investigated if thethe tumorigenesis experiments in vivo with the 453-5-
FO cell lines. Strikingly, the tumor formation from 453- IKK-induced tumorigenesis could be suppressed by
MG132. As shown in Figure 6H, inoculation of MG1325-FO5 or -FO18 in nude mice was reduced (Figure 6G),
IKK Represses FOXO3a
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Figure 7. Downregulation of Endogenous FOXO3a Contributes to Tumorigenesis whereas Ectopic Expression of FOXO3a Leads to Tumor
Suppression
(A) Lysates of 453 and ip1 transfected with FOXO3a-siRNA or control RNA were analyzed by IB.
(B) 453-5 cells transfected with FOXO3a-siRNA or control RNA were injected into the mammary fat pads of nude mice.
(C) 231 cells transfected with FOXO3a-siRNA or control RNA were injected into the mammary fat pads of nude mice.
(D) 453 and 231 were transfected with a FOXO3a or control vector, followed by G418 selection for stable clones.
(E) 231 or 231-FOXO3a cells were injected into the mammary fat pads of nude mice.
(F) A diagram depicts the IKK-mediated cooperative antiapoptotsis signaling pathways (dashed lines, normal regulations of IB and FOXO3a
on cellular targets in the absence of IKK activity).
into the 453-5-bearing mice significantly suppressed To further determine whether FOXO3a has a general
suppression effect for tumorigenesis, we transfectedtumorigenesis, suggesting that a mechanism underlying
IKK-mediated tumorigenesis in vivo may be through MDA-MB-231 (231) cells with FOXO3a-siRNA or control
siRNA and injected the transfected cells into the mam-inhibition of FOXO3a.
To examine whether IKK-mediated tumorigenesis is mary fat pads of nude mice. We found that FOXO3a-
siRNA in 231 also increased tumorigenesis in nude micedue to inhibition of FOXO3a function, we carried out
siRNA-mediated gene silencing to confirm if IKK-medi- (Figure 7C), suggesting that downregulation of FOXO3a
can enhance tumorigenesis in vivo. In contrast, ectopicated tumorigenesis could be enhanced by further down-
regulation of residual FOXO3a in 453-5 cells. We first expression of FOXO3a in 453 and 231 by DNA transfec-
tion inhibited colony formation in vitro (Figure 7D); anddetermined if FOXO3a-siRNA could affect endogenous
FOXO3a expression by IB with an anti-FOXO3a after the ability of tumorigenesis of the FOXO3a-transfected
231 (designated as 231-FOXO3a) in nude mice was im-cells were transfected with FOXO3a-siRNA or control
siRNA. Indeed, FOXO3a-siRNA specifically decreased paired (Figure 7E). Taken together, our results strongly
suggest that FOXO3a has a general suppression effectFOXO3a expression in 453 and ip1 cells (Figure 7A).
We then tested whether downregulation of FOXO3a can for tumorigenesis in vivo.
affect tumorigenesis by transfecting 453-5 with
FOXO3a-siRNA or control siRNA and then injecting the Discussion
transfected cells into the mammary fat pads of nude
mice. Strikingly, FOXO3a-siRNA in 453-5 augmented Nuclear exclusion of FOXO3a in human primary tumors
lacking Akt activity has not been elucidated, and itstumor growth in nude mice significantly (Figure 7B), sug-
gesting that 453-5-induced tumorigenesis is through pathological or clinical significance has not been re-
ported. Our results indicate a new mechanism for andownregulation of FOXO3a.
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Akt-independent inhibition of FOXO3a that promotes vents tumor cell survival or resistance to apoptosis is
cell proliferation and tumorigenesis. Our findings point necessary for understanding the molecular basis for its
to a striking inverse correlation between cytoplasmic tumor suppression activity or application as an anti-
FOXO3a and the survival rate in breast cancer, sug- cancer agent for therapeutic intervention.
gesting that FOXO3a may become a novel prognostic
biomarker for cancer survival. In addition, FOXO3a may
Experimental Procedures
be a new tool for a therapeutic or preventive intervention
for breast cancer and perhaps other types of cancer. Immunohistochemical Staining
IHC staining was performed as described (Deng et al., 2002). TissueThe molecular mechanisms by which the FOXO fac-
sections were incubated with anti-Akt-p (Thr308) and -Akt-ptors inhibit tumorigenesis are not fully elucidated yet.
(Ser473), two anti-FOXO3a Ab, and two anti-IKK Ab. Sections wereOur results indicate that FOXO3a is a cellular target for
treated with biotin-conjugated 2nd Ab and followed by avidin biotin-IKK and its fate after phosphorylation by IKK appears
peroxidase complex and amino-ethyl carbazole chromogen.
to be similar to those of members of the IB family with Kaplan-Meier survival curves were generated using scores of posi-
regards to their cytoplasmic retention, Ub, and degrada- tive versus negative Akt-p and IKK, positive IKK and cytoplasmic
tion. A schematic representation of the IKK-mediated FOXO3a versus negative IKK plus nuclear FOXO3a, or positive
Akt-p and IKK and FOXO3a versus negative Akt-p and IKK andphosphorylation, Ub, and proteolysis of FOXO3a and
nuclear FOXO3a as strata. Two-sided log-rank analysis was used toIB in the parallel antiapoptotic signaling pathways is
assess statistical significance, and the association between discreteproposed (Figure 7F). This model is unique and impor-
variables was tested using the c2 test.
tant for the following reasons. Firstly, it provides a mech-
anism by which a cancer cell may acquire sustained
Plasmids, Antibodies (Ab), Luciferase (Luc),resistance to apoptosis through an orchestrated inhibi-
and Immunofluorescence Assaystion of FOXO3a and IB by IKK, which can lead to consti-
The HA- and Myc-tagged FOXO3a expression plasmids were con-tutive survival signaling. Secondly, it suggests that stim-
structed by subcloning of wt FOXO3a containing HA-tag or Myc-
ulation of cell proliferation and tumorigenesis by NF-B tag using PCR. Plasmids of wt FOXO3a, FRE-Luc, FOXO3a-A3,
may require a concurrent inhibition of FOXO3a, whereas p27Kip1-Luc, pFasL-Luc, and IKK were kindly provided by K. Arden,
NF-B activation alone may not be sufficient to promote M. Greenberg, B. Burgering, C. Paya, B. Zhou, and K. Jeang. The
various FOXO3a-GFP and -GST fusion vectors were constructed bytumorigenesis but activate certain NF-B target genes,
subcloning of the DNA fragments of full-length or an indicated do-which induce the production of inflammatory cytokines
main of FOXO3a. The S644A mutant FOXO3a DNA was generatedor chemokines that may trigger recruitment of the im-
using QuickChange site-directed mutagenesis (Stratagene) tomune cells to the tumors and cause their rejections. This
change the Ser644 residue to Ala644 and confirmed by DNA se-
may explain why NF-B can also contribute to tumor quencing. Ab against the phosphorylation site of FOXO3a-
suppression under certain circumstances although NF- S644 were produced with a synthetic phosphorylated peptide
B activation has been largely associated with the devel- DGLDFNFDpSLISTQNVVGL and purified with the phosphopeptide
column at Bethyl Laboratories, Inc, Montgomery, Texas. Luc assaysopment of a variety of malignancies (Deng et al., 2002;
were performed using Dual-Luciferase Assay (Promega). For immu-Karin et al., 2002). Thirdly, blocking NF-B activity has
nofluorescence, 293T were cotransfected with FOXO3a-GFP or mu-been viewed as a promising approach to inhibit tumor
tant FOXO3a-(S644A)-GFP plus the indicated IKK vectors. After fixa-
proliferation or increase the sensitivity of cancer cells tion, the cells were stained with an anti-Flag and a Texas Red-2nd
to chemotherapeutic drugs. Intense efforts have been Ab, and the cellular localizations of FOXO3a and IKK were deter-
underway to identify small molecule antagonists for IKK mined under a fluorescent microscope.
or NF-B as promising chemotherapeutic drugs (Karin
et al., 2002). Our model suggests that IKK should be
Immunoprecipitation, Immunoblotting, Kinase,
the therapeutic target of choice and the IKK-specific and GST Pulldown Assays
antagonists may be more useful than general inhibitors We carried out IP, IB, and kinase assays as described (Deng et al.,
of NF-B for inducing apoptosis of most types of tumors, 2002; Zhou et al., 2000). For in vivo kinase assay, 293T cells were
cotransfected with the indicated vectors. After 36 hr, cells werewith or without constitutive NF-B activity (Karin et
starved in serum-free and phosphate-free medium for 12 hr andal., 2002).
incubated in phosphate-free medium supplemented with 1 mCi/mlBased on our findings, we propose a model for an
[32P]orthophosphate for 3 hr. HA-FOXO3a was IP with an anti-HA,IKK-dependent repression of FOXO3a that promotes
subjected to SDS-PAGE and autoradiography. GST pulldown assays
cell growth and tumorigenesis. However, we cannot rule were performed as described (Deng et al., 2002).
out one possible mechanism by which overexpression
of FOXO3a in cells may predominantly occupy functional
Cell Culture, Cell Cycle Analysis, and Proliferation AssayIKK and abolish the IKK-mediated proteolysis of IB,
Cells were cultured in DMEM/F12 supplemented with 10% fetalresulting in sustained retention of the IB/NF-B com-
bovine serum (FBS). Transient or stable transfections of cells with
plex in the cytoplasm that leads to suppression of cell DNAs were performed with an optimal ratio of DNAs and liposome.
proliferation and tumorigenesis. This mechanism will im- Stable cell lines were isolated with G418 or puromycin selection.
ply that the inhibitory effect of FOXO3a in the IKK- For colony assays, cells were transfected with DNAs. After G418
mediated cell growth and tumorigenesis may be via selection, the cells were stained with crystal violet, and the average
number of colonies and standard deviation were calculated basedinactivation of NF-B. Alternatively, the observed
on three independent replicates. For cell cycle analysis, cells wereFOXO3a-mediated suppression of cell growth and tu-
serum starved and incubated in medium containing mimosine (400morigenesis in our breast cancer animal models may be

M) for 30 hr. Cells were harvested at 0, 4, 8 hr after replacing the
attributed to cooperative upregulation of the FOXO3a- medium with fresh medium with 10% FBS, stained with propidium
induced proapoptotic genes and downregulation of the iodide, and subjected to FACS analysis. Cell proliferation rates were
NF-B-mediated antiapoptotic genes. Further investiga- measured by direct cell counting using a counting chamber with
trypan blue.tion of the signaling mechanism by which FOXO3a pre-
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ChIP Assays inhibits NF-B in human colon and breast cancer. Cancer Cell 2,
323–334.The ChIP assays were carried out as described (Lin et al., 2001;
Weinmann and Farnham, 2002). Briefly, cells were fixed with formal- Hanahan, D., and Weinberg, R.A. (2000). The hallmarks of cancer.
dehyde, washed, resuspended in hypotonic buffer, passed through Cell 100, 57–70.
a 25-gauge needle, sonicated, and lysates containing soluble chro- Joyce, D., Albanese, C., Steer, J., Fu, M., Bouzahzah, B., and Pestell,
matin were prepared and incubated with Ab. DNA-protein immun- R.G. (2001). NF-B and cell-cycle regulation: the cyclin connection.
complexes were collected with protein A-agarose beads, washed, Cytokine Growth Factor Rev. 12, 73–90.
treated with RNase A, and followed by incubation with proteinase
Karin, M., and Ben-Neriah, Y. (2000). Phosphorylation meets Ub: theK at 65C; the DNA samples were extracted with phenol/chloroform
control of NF-B activity. Annu. Rev. Immunol. 18, 621–663.and precipitated with ethanol. Specific sequences of human
Karin, M., Cao, Y., Greten, F.R., and Li, Z.W. (2002). NF-B in cancer:p27Kip1 gene promoter in the DNA samples were detected by PCR
from innocent bystander to major culprit. Nat. Rev. Cancer 2,with primers 5GTCTTCTACCAGGGTCCACC3 and 5CACTTCGAT
301–310.CCCCTTCACATG3.
Kops, G.J., Medema, R.H., Glassford, J., Essers, M.A., Dijkers, P.F.,
SiRNA Coffer, P.J., Lam, E.W., and Burgering, B.M. (2002). Control of cell
Cells were transfected with FOXO3a-siRNA (5GAGCUCUUGGUG cycle exit and entry by protein kinase B-regulated forkhead tran-
GAUCAUCTT3) or control luc RNA (5GAGCUCUUGGUGGAU scription factors. Mol. Cell. Biol. 22, 2025–2036.
CAUCTT3) duplex (Dharmacon) (4 
M/2 106 cells) by Lipofectam- Lin, S.-Y., Makino, K., Xia, W., Matin, A., Wen, Y., Kwong, K.Y.,
ine 2000 (Invitrogen) or electroporation using Nucleofector 1 Bourguignon, L., and Hung, M.-C. (2001). Nuclear localization of
(amaxa), and lysates prepared 48 hr after transfection. EGF receptor and its potential new role as a transcription factor.
Nat. Cell Biol. 3, 802–808.
Animal Studies Medema, R.H., Kops, G.J., Bos, J.L., and Burgering, B.M. (2000).
We performed tumorigenesis assays in an orthotopic breast cancer AFX-like Forkhead transcription factors mediate cell-cycle regula-
mouse model (Chang et al., 1997). Cells were injected (2  106 cells) tion by Ras and PKB through p27kip1. Nature 404, 782–787.
into the mammary fat pads of nude mice (n  10/group), the tumor
Nakamura, N., Ramaswamy, S., Vazquez, F., Signoretti, S., Loda, M.,volumes were measured twice weekly, and the data were tested
and Sellers, W.R. (2000). Forkhead transcription factors are criticalstatistically using two-sided long-rank analysis. For MG132 treat-
effectors of cell death and cell cycle arrest downstream of PTEN.ment, cells were pretreated with MG132 (5 
g/ml) or DMSO for 6
Mol. Cell. Biol. 20, 8969–8982.hr before injection into the mammary fat pads of nude mice. One
Nicholson, K.M., and Anderson, N.G. (2002). The protein kinaseweek after inoculation, MG132 (5 nmole/mouse) or DMSO (100 
l)
B/Akt signaling pathway in human malignancy. Cell. Signal. 14,was injected into the tumor-bearing mice twice/week. For siRNA
381–395.treatment, cells were transfected with siRNA 24 hr before injection
into the mammary fat pads of nude mice. The data were tested Puig, O., Marr, M.T., Ruhf, M.L., and Tjian, R. (2003). Control of cell
statistically using the t test. number by Drosophila FOXO: downstream and feedback regulation
of the insulin receptor pathway. Genes Dev. 17, 2006–2020.
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